Law360, New York (March 23, 2007, 12:00 AM ET) -- Amid growing concerns over the anti-competitive effects of deals that keep generics off the market, the U.S. Federal Trade Commission subpoenaed Cephalon Inc. for information regarding its patent infringement settlements for sleep disorder drug Provigil.
On Friday, Cephalon revealed in a filing with the Securities and Exchange Commission that the FTC had asked for additional material after first approaching the biopharmaceutical giant for information last July.
“The Company intends to continue to cooperate fully with this investigation,” Cephalon stated while it tried to downplay the potential...
FTC Taps Cephalon Again Over Provigil Deal
To view the full article, take a free trial now.
